

George M Shaw

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3515076/george-m-shaw-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104
papers

18,269
citations

49
h-index

108
g-index

108
ext. papers

20,522
ext. citations

14.6
avg, IF

5.45
L-index

#	Paper	IF	Citations
104	Potent anti-viral activity of a trispesific HIV neutralizing antibody in SHIV-infected monkeys.. <i>Cell Reports</i> , 2022 , 38, 110199	10.6	3
103	Zoonotic origin of the human malaria parasite Plasmodium malariae from African apes.. <i>Nature Communications</i> , 2022 , 13, 1868	17.4	0
102	CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	1
101	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021 , 184, 2955-2972.e25	56.2	22
100	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure. <i>Journal of Virology</i> , 2021 ,	6.6	7
99	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021 , 371,	33.3	22
98	The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. <i>PLoS Pathogens</i> , 2021 , 17, e1009257	7.6	9
97	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2021 , 95, e0079621	6.6	1
96	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2021 , 17, e1009736	7.6	3
95	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	14
94	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. <i>Nature Medicine</i> , 2020 , 26, 932-940	50.5	60
93	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020 , 31, 107624	10.6	19
92	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. <i>Journal of Virology</i> , 2020 , 94,	6.6	2
91	Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST. <i>MBio</i> , 2020 , 11,	7.8	2
90	Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 T Cells. <i>Journal of Virology</i> , 2020 , 95,	6.6	11
89	Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. <i>PLoS ONE</i> , 2020 , 15, e0235237	3.7	2
88	SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. <i>Journal of Virology</i> , 2020 , 94,	6.6	17

87	Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model. <i>MBio</i> , 2019 , 10,	7.8	9
86	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019 , 26, 336-346.e3	23.4	43
85	Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. <i>Journal of Virology</i> , 2019 , 93,	6.6	12
84	Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. <i>Journal of Virology</i> , 2019 , 93,	6.6	7
83	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019 , 15, e1007632	7.6	9
82	CD4 receptor diversity in chimpanzees protects against SIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 3229-3238	11.5	12
81	High multiplicity infection following transplantation of hepatitis C virus-positive organs. <i>Journal of Clinical Investigation</i> , 2019 , 129, 3134-3139	15.9	4
80	Molecular Identification of Transmitted/Founder Hepatitis C Viruses and Their Progeny by Single Genome Sequencing. <i>Methods in Molecular Biology</i> , 2019 , 1911, 139-155	1.4	3
79	Contribution of proteasome-catalyzed peptide -splicing to viral targeting by CD8 T cells in HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 24748-24759	11.5	27
78	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019 , 50, 241-252.e6	32.3	96
77	Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E7139-E7148	11.5	13
76	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. <i>Cell Host and Microbe</i> , 2018 , 24, 717-730.e5	23.4	47
75	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. <i>Cell Reports</i> , 2018 , 25, 893-908.e7	10.6	65
74	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , 2018 , 9, 1928	17.4	46
73	Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E590-E599	11.5	92
72	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017 , 91,	6.6	30
71	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	127
70	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017 , 13, e1006510	7.6	33

69	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. <i>JCI Insight</i> , 2017 , 2,	9.9	75
68	Wild bonobos host geographically restricted malaria parasites including a putative new <i>Laverania</i> species. <i>Nature Communications</i> , 2017 , 8, 1635	17.4	28
67	Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. <i>Retrovirology</i> , 2017 , 14, 35	3.6	6
66	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. <i>Journal of Virology</i> , 2016 , 90, 8435-53	6.6	16
65	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E3413-22	11.5	132
64	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016 , 19, 292-303	23.4	108
63	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016 , 165, 449-63	56.2	209
62	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. <i>Journal of Virology</i> , 2016 , 90, 152-66	6.6	16
61	Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. <i>PLoS Pathogens</i> , 2016 , 12, e1005879	7.6	14
60	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. <i>PLoS Pathogens</i> , 2016 , 12, e1005537	7.6	39
59	Collapse of Cytolytic Potential in SIV-Specific CD8+ T Cells Following Acute SIV Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2016 , 12, e1006135	7.6	15
58	Multigenomic Delineation of Plasmodium Species of the <i>Laverania</i> Subgenus Infecting Wild-Living Chimpanzees and Gorillas. <i>Genome Biology and Evolution</i> , 2016 , 8, 1929-39	3.9	28
57	Genomes of cryptic chimpanzee Plasmodium species reveal key evolutionary events leading to human malaria. <i>Nature Communications</i> , 2016 , 7, 11078	17.4	100
56	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016 , 14, 97-111	8.8	29
55	HIV-1 Vpu Mediates HLA-C Downregulation. <i>Cell Host and Microbe</i> , 2016 , 19, 686-95	23.4	81
54	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. <i>EBioMedicine</i> , 2016 , 3, 122-134	8.8	53
53	Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. <i>MBio</i> , 2015 , 6, e02518	7.8	13
52	Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. <i>PLoS Pathogens</i> , 2015 , 11, e1004565	7.6	39

51	Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length. <i>Journal of Virology</i> , 2015 , 89, 11056-68	6.6	22
50	Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. <i>MBio</i> , 2015 , 6,	7.8	19
49	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015 , 18, 354-62	23.4	53
48	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. <i>Virology</i> , 2015 , 475, 37-45	3.6	21
47	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015 , 7, 5443-75	6.2	20
46	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015 , 11, e1005042	7.6	111
45	Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver. <i>MBio</i> , 2015 , 6, e02510	7.8	13
44	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. <i>Cell</i> , 2014 , 158, 481-96.2	36.2	213
43	Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. <i>Cell Host and Microbe</i> , 2014 , 16, 412-8	23.4	41
42	African origin of the malaria parasite <i>Plasmodium vivax</i> . <i>Nature Communications</i> , 2014 , 5, 3346	17.4	137
41	Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A58-A58	1.6	2
40	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. <i>Open Forum Infectious Diseases</i> , 2014 , 1, ofu056	1	12
39	Relative resistance of HIV-1 founder viruses to control by interferon-alpha. <i>Retrovirology</i> , 2013 , 10, 146	3.6	142
38	Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. <i>Virology</i> , 2013 , 436, 33-48	3.6	50
37	Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. <i>Journal of Virology</i> , 2013 , 87, 4185-201	6.6	80
36	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013 , 496, 469-76	50.4	759
35	Phenotypic properties of transmitted founder HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6626-33	11.5	293
34	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. <i>Journal of Clinical Investigation</i> , 2013 , 123, 380-93	15.9	141

33	HIV transmission. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012 , 2,	5.4	197
32	Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. <i>PLoS Pathogens</i> , 2012 , 8, e1002881	7.6	118
31	Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. <i>PLoS Pathogens</i> , 2012 , 8, e1002721	7.6	143
30	Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. <i>PLoS Pathogens</i> , 2012 , 8, e1002880	7.6	67
29	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. <i>Journal of Virology</i> , 2011 , 85, 9998-10009	6.6	342
28	An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. <i>Journal of Virology</i> , 2011 , 85, 7029-36	6.6	180
27	Wide variation in the multiplicity of HIV-1 infection among injection drug users. <i>Journal of Virology</i> , 2010 , 84, 6241-7	6.6	167
26	Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. <i>Journal of Virology</i> , 2010 , 84, 10406-12	6.6	105
25	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. <i>PLoS Pathogens</i> , 2010 , 6, e1000890	7.6	219
24	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1253-72	16.6	500
23	Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. <i>PLoS Pathogens</i> , 2009 , 5, e1000274	7.6	253
22	HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. <i>PLoS Pathogens</i> , 2009 , 5, e1000414	7.6	146
21	Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. <i>Journal of Virology</i> , 2009 , 83, 1240-59	6.6	61
20	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1117-34	16.6	257
19	Modeling sequence evolution in acute HIV-1 infection. <i>Journal of Theoretical Biology</i> , 2009 , 261, 341-60	2.3	128
18	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1273-89	16.6	600
17	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 7552-7	11.5	1472
16	Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. <i>Journal of Virology</i> , 2008 , 82, 3952-70	6.6	487

15	Simian Immunodeficiency Virus Infection in Free-Ranging Sooty Mangabeys (<i>Cercocebus atys atys</i>) from the Tai Forest, Co te dIvoire: Implications for the Origin of Epidemic Human Immunodeficiency Virus Type 2. <i>Journal of Virology</i> , 2006 , 80, 4645-4645	6.6	2
14	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. <i>Journal of Experimental Medicine</i> , 2005 , 201, 1407-19	16.6	264
13	Antibody neutralization and escape by HIV-1. <i>Nature</i> , 2003 , 422, 307-12	50.4	1978
12	Molecular characterization of a highly divergent HIV type 1 isolate obtained early in the AIDS epidemic from the Democratic Republic of Congo. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 1217-22	1.6	13
11	Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 675-88	1.6	73
10	Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. <i>Nature Medicine</i> , 1998 , 4, 1302-7	50.5	900
9	Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?. <i>Immunological Reviews</i> , 1998 , 164, 37-51	11.3	49
8	Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. <i>Nature Medicine</i> , 1997 , 3, 205-11	50.5	1041
7	Viral dynamics in human immunodeficiency virus type 1 infection. <i>Nature</i> , 1995 , 373, 117-22	50.4	2863
6	Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. <i>Nature</i> , 1994 , 370, 463-7	50.4	557
5	Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. <i>Nature</i> , 1992 , 358, 495-9	50.4	391
4	Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. <i>Cell</i> , 1986 , 45, 637-48	56.2	687
3	Oral clade C SHIV challenge models to study pediatric HIV-1 infection by breastmilk transmission		1
2	Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques		4
1	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure		1